EPO‐INT‐1.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 246, ovarian cancer (stage I‐IV); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = a: 150 IU/kg sc TIW; b: 300 IU/kg sc TIW hb‐target = 12.5 to 14 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: transfusion; secondary: Hb change, Hct, QoL
Notes	study number = 53915
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Unclear risk	no description